BRWA
CRBP icon

B. Riley Wealth Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

B. Riley Wealth Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-713
Closed -$2.37K – 1541
2022
Q4 		$2.37K Buy
+713
New +$2.74K ﹤0.01% 1489

Other funds holding CRBP

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

B. Riley Wealth Advisors's CRBP Position: Q1 2023 in Review

B. Riley Wealth Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q1 2023, closing a stake of 713 shares — an estimated $2.37K sold.

B. Riley Wealth Advisors first reported a position in CRBP in Q4 2022 and held it in 1 quarter. The position peaked at $2.37K in Q4 2022. 30 funds tracked by Wall St. Rank hold CRBP as of Q1 2023.

  • B. Riley Wealth Advisors reported no remaining Corbus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 713 Corbus Pharmaceuticals shares in Q1 2023, an estimated $2.37K.
  • B. Riley Wealth Advisors first reported a position in Corbus Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • B. Riley Wealth Advisors's Corbus Pharmaceuticals position peaked at $2.37K in Q4 2022.
  • 30 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2023.

Based on B. Riley Wealth Advisors's 13F filing for Q1 2023, filed 17 May 2023.